Evidence map›Paper›PMID 29152585›Full record

ArticlemSystems

Total Lipopolysaccharide from the Human Gut Microbiome Silences Toll-Like Receptor Signaling.

Eva d'Hennezel, Sahar Abubucker, Leon O Murphy, Thomas W Cullen

Open access · goldAbstract read
In one paragraph

Article in mSystems. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 209 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
209citing papers in PubMed, 4 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

209 citing papers in PubMed, 4 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Review
  8. Enteric-colonizedGut microbes · 2026
    Article
  9. Bridging the gap:Gut microbes · 2026
    Review
  10. Review
  11. Article
  12. Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. bioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Review

149 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eva d'HennezelDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts, USA.
Sahar AbubuckerDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts, USA.
Leon O MurphyDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts, USA.
Thomas W CullenDevelopmental and Molecular Pathways, Novartis Institutes for Biomedical Research Inc., Cambridge, Massachusetts, USA.
Novartis (United States) · USPathways Behavioral Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cohabitation of microbial communities with the host enables the formation of a symbiotic relationship that maintains homeostasis in the gut and beyond. One prevailing model suggests that this relationship relies on the capacity of host cells and tissues to remain tolerant to the strong immune stimulation generated by the microbiota such as the activation of Toll-like receptor 4 (TLR4) pathways by lipopolysaccharide (LPS). Indeed, gut microbial LPS is thought to be one of the most potent activators of innate immune signaling and an important mediator of the microbiome's influence on host physiology. In this study, we performed computational and experimental analyses of healthy human fecal samples to examine the TLR4 signaling capacity of the gut microbiota. These analyses revealed that an immunoinhibitory activity of LPS, conserved across the members of the order

Indexed as

lipopolysaccharidemicrobial communitiesmicrobiomesymbiosistoleranceToll-like receptors

Identifiers

PMID29152585
PMCPMC5686520
OpenAlexW2770311021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.